Drug points: Rimonabant may induce atrial fibrillation

BMJ (Online)

Volumn 339, Issue 7715, 2009, Pages 296-

  Cocco, Giuseppe ^a   Chu, David ^a  

^a Cardiology Office   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATORVASTATIN; LOW MOLECULAR WEIGHT HEPARIN; METFORMIN; METOPROLOL; PHENPROCOUMON; RIMONABANT; VALSARTAN; ANTIOBESITY AGENT; FATTY ACID; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INSOMNIA; LIFESTYLE MODIFICATION; NAUSEA; OBESITY; PRIORITY JOURNAL; SINUS RHYTHM; STRESS ECHOCARDIOGRAPHY; THYROID FUNCTION TEST; CHEMICALLY INDUCED DISORDER; MALE; METABOLISM; REVIEW;

ANTI-OBESITY AGENTS; ATRIAL FIBRILLATION; FATTY ACIDS, NONESTERIFIED; HUMANS; MALE; PIPERIDINES; PYRAZOLES;

EID: 68149136733     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b1061     Document Type: Article

References (15)

1. Després JP, Golay A, Sjöström L (for the Rimonabant in Obesity-Lipids Study Group). Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134[Abstract/ Free Full Text]
2. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin JMS, Rosenstock J (for the RIO-North America Study Group). Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. JAMA 2006;295:761-775[Abstract/Free Full Text]
3. Gelfand EV, Cannon CP. Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. J Am Coll Cardiol 2006;47:1919-1926[Abstract/Free Full Text]
4. Padwal R, Majumdar S. Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 2007;369:71-77[CrossRef][Web of Science][Medline] (Pubitemid 46027230)
5. Schellekens S, Verheught FWA. Hotline sessions of the 26th European Congress of Cardiology. Eur Heart J 2004;25:2164-2166[Free Full Text] (Pubitemid 39572250)
6. Stöckli R, Keller U. Cannabinoid-blockade verbessert das metabolische syndrom - weniger lust am essen, aber manchmal auch weniger lust am leben. Swiss Medical Forum 2008;8:356-360
7. Chistensen R, Kristensen P, Bartels E, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-1713[CrossRef][Web of Science] [Medline] (Pubitemid 350100788)
8. FDA. FDA briefing document. 2007 http://www.fda.gov/ohrms/dockets/ac/07/ briefing/2007-4306b1-fda-backgrounder.pdf.
9. Boder G. Effects of free fatty acids on glucose metabolism: significance for insulin resistance and type 2 diabetes. Exp Clin Endocrinol Diabetes 2003;111:121-124[CrossRef][Web of Science][Medline]
10. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodelling. Circulation 2007;116:2101-2109[Abstract/Free Full Text] (Pubitemid 350060347)
11. Gesch B, Hammond SM, Hampson SE, Eves A, Crowder MJ. Influence of supplementary vitamins, minerals, and essential fatty acids on the antisocial behavior of young adult prisoners. Br J Psych 2000;181:22-28[CrossRef]
12. Boullier A, Friedman P, Harkewicz R, Hartvigsen K, Green SR, Almazan F, et al. Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res 2005;46:969-976[Abstract/Free Full Text] (Pubitemid 43309220)
13. Richardson AJ, Montgomery P. The Oxford-Durham study: a randomized controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005;115:1360-1366[Abstract/Free Full Text] (Pubitemid 43843244)
14. MacLean F, Lee A. Drug-induced cardiovascular disorders. Pharmaceutical J 1999;262:113-118
15. Nissen SE, Nicholls J, Wolski K, Rodés-Cabau J, Cannon CP, Deanfileld JE (for the STRADIVARIUS Investigators). Effects of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease. The STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1960[Abstract/Free Full Text]